Unnamed Document

Total Page:16

File Type:pdf, Size:1020Kb

Unnamed Document Mutations M287L and Q266I in the Glycine Receptor ␣1 Subunit Change Sensitivity to Volatile Anesthetics in Oocytes and Neurons, but Not the Minimal Alveolar Concentration in Knockin Mice Cecilia M. Borghese, Ph.D.,* Wei Xiong, Ph.D.,† S. Irene Oh, B.S.,‡ Angel Ho, B.S.,§ S. John Mihic, Ph.D.,ʈ Li Zhang, M.D.,# David M. Lovinger, Ph.D.,** Gregg E. Homanics, Ph.D.,†† Edmond I. Eger 2nd, M.D.,‡‡ R. Adron Harris, Ph.D.§§ ABSTRACT What We Already Know about This Topic • Inhibitory spinal glycine receptor function is enhanced by vol- Background: Volatile anesthetics (VAs) alter the function of atile anesthetics, making this a leading candidate for their key central nervous system proteins but it is not clear which, immobilizing effect if any, of these targets mediates the immobility produced by • Point mutations in the ␣1 subunit of glycine receptors have been identified that increase or decrease receptor potentiation VAs in the face of noxious stimulation. A leading candidate is by volatile anesthetics the glycine receptor, a ligand-gated ion channel important for spinal physiology. VAs variously enhance such function, and blockade of spinal glycine receptors with strychnine af- fects the minimal alveolar concentration (an anesthetic What This Article Tells Us That Is New EC50) in proportion to the degree of enhancement. • Mice harboring specific mutations in their glycine receptors Methods: We produced single amino acid mutations into that increased or decreased potentiation by volatile anesthetic in vitro did not have significantly altered changes in anesthetic the glycine receptor ␣1 subunit that increased (M287L, third potency in vivo transmembrane region) or decreased (Q266I, second trans- • These findings indicate that this glycine receptor does not me- membrane region) sensitivity to isoflurane in recombinant diate anesthetic immobility, and that other targets must be receptors, and introduced such receptors into mice. The re- considered sulting knockin mice presented impaired glycinergic trans- mission, but heterozygous animals survived to adulthood, * Research Associate, ʈ Associate Professor, §§ Professor, The and we determined the effect of isoflurane on glycine-evoked University of Texas at Austin, Waggoner Center for Alcohol and responses of brainstem neurons from the knockin mice, and Addiction Research, Austin, Texas. † Research Fellow, # Medical Officer, ** Laboratory Chief, Laboratory for Integrative Neurosci- the minimal alveolar concentration for isoflurane and other ence, National Institute on Alcohol Abuse and Alcoholism, National VAs in the immature and mature knockin mice. Institutes of Health, Rockville, Maryland. ‡ Staff Research Associate, Results: Studies of glycine-evoked currents in brainstem ‡‡ Professor Emeritus, Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, Califor- neurons from knockin mice confirmed the changes seen with nia. § Staff Research Assistant, Diabetes Center, University of Cali- recombinant receptors. No increases in the minimal alveolar fornia San Francisco. †† Professor, Departments of Anesthesiology concentration were found in knockin mice, but the minimal and Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania. alveolar concentration for isoflurane and enflurane (but not Received from the Waggoner Center for Alcohol and Addiction halothane) decreased in 2-week-old Q266I mice. This Research, The University of Texas at Austin, Austin, Texas. Submit- change is opposite to the one expected for a mutation that ted for publication October 10, 2011. Accepted for publication June decreases the sensitivity to volatile anesthetics. 7, 2012. Supported by grant nos. 1PO1GM47818 and AA06399 from the National Institutes of Health, Bethesda, Maryland. Drs. Xiong, Conclusion: Taken together, these results indicate that gly- Zhang, and Lovinger acknowledge support from the Division of cine receptors containing the ␣1 subunit are not likely to be Intramural Clinical and Biomedical Research, National Institute on crucial for the action of isoflurane and other VAs. Alcohol Abuse and Alcoholism, National Institutes of Health, Rock- ville, Maryland. Address correspondence to Dr. Harris: The University of PRESENT consensus suggests that volatile anesthetics Texas at Austin, Waggoner Center for Alcohol and Addiction (VAs) bind to proteins to produce their effects, includ- Research, 1 University Station A4800, Austin, Texas 78712-0159. A 1 [email protected]. Information on purchasing reprints may ing immobility. The key question is, “Which proteins?” The be found at www.anesthesiology.org or on the masthead page at list of candidates is short.1–3 A top candidate is the glycine the beginning of this issue. ANESTHESIOLOGY’s articles are made receptor (GlyR). freely accessible to all readers, for personal use only, 6 months from the cover date of the issue. Evidence for the GlyR as a target for VA includes their Copyright © 2012, the American Society of Anesthesiologists, Inc. Lippincott localization and sensitivity to VAs. The RNAs encoding the 4 Williams & Wilkins. Anesthesiology 2012; 117:765–71 GlyR subunits are mostly in the spinal cord and brainstem, Anesthesiology, V 117 • No 4 765 October 2012 Glycine Receptors and Anesthesia and the spinal cord mediates the immobility effect of VA.5 in 50% of test subjects) of anesthetics in wild-type and Moreover, anesthetic concentrations of VAs substantially en- knockin mice. hance inhibitory currents through the GlyR, both in heter- ologous systems6–8 and neurons.8 More direct evidence Materials and Methods arises from the use of strychnine, a competitive GlyR-specific Knockin mouse production and the electrophysiological antagonist, both at the neuronal and whole animal level. The techniques were described in detail in Borghese et al.21 We application of halothane to decerebrate rats depressed the briefly describe them here, and add pertinent details. The spinal cord sensory neuronal activity to noxious stimuli; experimental work on animals conformed to the guidelines the concurrent application of strychnine partially reversed laid out in the Guide for the Care and Use of Laboratory the halothane-induced depression.9 Sevoflurane reduced Animals, and approval of the corresponding institutional spontaneous action potential firing of ventral horn interneu- Animal Care Committees was obtained. rons in cultured spinal cord tissue slices; application of Electrophysiology in Xenopus Oocytes strychnine decreased the sevoflurane effect.10 Intrathecal ad- Chloroform was purchased from Sigma-Aldrich (Saint ministration of strychnine increased the minimal alveolar Louis, MO), and isoflurane was purchased from Marsam concentration (MAC) of isoflurane.11 The magnitude of Pharmaceuticals (Cherry Hill, NJ). Isoflurane and chloro- GlyR potentiation expressed in oocytes varies according to 12 form solutions were prepared in buffer immediately before the VA used. Intrathecal administration of strychnine to application. rats anesthetized with halothane, isoflurane, or cyclopropane Manually isolated oocytes from Xenopus laevis frogs were increased MAC in proportion to the enhancement of GlyRs 13 injected in the nuclei with complementary DNA encoding observed in vitro . Furthermore, intrathecal glycine reduced ␣ 14 wild-type and mutated human 1 GlyR subunits. After 1–5 the isoflurane MAC in rats. These results are compatible days, recordings were carried out using the whole cell two- with the hypothesis that GlyRs partly mediate the capacity of electrode voltage clamp configuration. All drugs were ap- VAs to produce immobility. plied by bath-perfusion and solutions were prepared the day Construction of chimeric glycine-␥-aminobutyric acid of the experiment. To study the chloroform (1 mM) and type A receptors (GABAA-Rs) allowed the identification of isoflurane (0.3 mM) modulation of glycine currents, the gly- transmembrane amino acids crucial to the VAs’ action, cine concentration equivalent to 5% of the maximal glycine- namely S267 and A288 in the second and third GlyR trans- evoked current (EC5) was determined after applying the gly- 15 membrane domains. Mutation of S267 to cysteine and cine concentration that produced maximal current (3 mM for subsequent labeling with thiol-specific reagents blocked the wild-type, 10 mM for mutant). Glycine was removed with a VA potentiation of GlyRs.16,17 Furthermore, a crystal struc- washout of 5 min between all applications, except after ap- ture of a prokaryotic protein closely related to GlyR was plication of maximal glycine concentrations (15 min). After obtained in the presence of VAs and showed selective bind- two applications of EC5 glycine, each of the modulators was ing of the anesthetics to the regions proposed in the earlier preapplied for 1 min and then coapplied with glycine for 18 studies of GlyR. 30 s. EC5 glycine was applied between coapplication of gly- The identification of a mutation in a receptor that renders cine and modulator. The concentrations of isoflurane and it insensitive or hypersensitive to modulation by VAs would chloroform were chosen as equivalent to 1 x MAC.22 All allow construction of a knockin mouse that could be tested experiments shown include data obtained from oocytes for changes in the sensitivity to VAs. This approach was taken from at least two different frogs, and oocytes that pre- sented a maximal current more than 20 ␮A were not in- successful in showing that specific GABAA-Rs are responsi- ble for
Recommended publications
  • Electrophysiologic Evidence for Increased Endogenous Gabaergic but Not Glycinergic Inhibitory Tone in the Rat Spinal Nerve Ligation Model of Neuropathy Vesa K
    Anesthesiology 2001; 94:333–9 © 2001 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Electrophysiologic Evidence for Increased Endogenous GABAergic but Not Glycinergic Inhibitory Tone in the Rat Spinal Nerve Ligation Model of Neuropathy Vesa K. Kontinen, M.D., Ph.D.,* Louise C. Stanfa, Ph.D.,† Amlan Basu,‡ Anthony H. Dickenson, Ph.D.§ Background: Changes in the inhibitory activity mediated by There is evidence that both GABA and glycinergic inter- ␥-aminobutyric acid (GABA) and glycine, acting at spinal GABA A neurons are preferentially associated with the control of receptors and strychnine-sensitive glycine receptors, are of in- 6–9 terest in the development of neuropathic pain. There is ana- low-threshold afferent input to the spinal cord. Con- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/94/2/333/402482/0000542-200102000-00024.pdf by guest on 29 September 2021 tomic evidence for changes in these transmitter systems after sistent with this, intrathecal administration of the 10 nerve injuries, and blocking either GABAA or glycine receptors GABAA-receptor antagonist bicuculline or the glycine- has been shown to produce allodynia-like behavior in awake receptor antagonist strychnine10,11 produces segmen- normal animals. tally localized tactile allodynia-like behavior in conscious Methods: In this study, the possible changes in GABAergic and glycinergic inhibitory activity in the spinal nerve ligation rats and increased responses to mechanical stimulation 12 model of neuropathic pain were studied by comparing the in anesthetized cats. Intrathecal strychnine has also effects of the GABAA-receptor antagonist bicuculline and the been shown to produce in anesthetized rats reflex re- glycine-receptor antagonist strychnine in neuropathic rats to sponses similar to those produced by nociceptive stim- their effects in sham-operated and nonoperated control rats.
    [Show full text]
  • Cyclopropane Anaesthesia by JOHN BOYD, M.D., D.A
    Cyclopropane Anaesthesia By JOHN BOYD, M.D., D.A. TLHIS paper is based on my experience of one thousand cases of cyclopropane anaesthesia personally conducted by me since October, 1938, both in hospital and in private. But before discussing these it might be convenient for me to mention here something about the drug itself. HISTORY. Cyclopropane was first isolated in Germany in 1882 by Freund, who also demonstrated its chemical structure, C3H6. He did not, however, describe its anaesthetic properties. Following its discovery it seems to have been forgotten until 1928, when Henderson and Lucas of Toronto, in investigating contaminants of propylene, another anesthetic with undesirable side-effects, and itself'an isomer of cyclopropane, found that the supposed cause of the cardiac disturbances was in reality a better and less toxic anaesthetic. They demonstrated its anaesthetic properties first on animals, and then, before releasing it to the medical profession for clinical trial, they anaesthetised each other, and determined the quantities necessary for administration to man. In 1933 the first clinical trials of cyclopropane were made by Waters and his associates of the University of Wisconsin. In October of that year Waters presented a preliminary report on its anaesthetic properties in man,1 confirming the findings of Henderson and Lucas. Rowbotham introduced it to England first in 1935, and since then its use has spread rapidly throughout the country. PREPARATION. Cyclopropane is prepared commercially by the reduction of trimethylene bromide in the presence of metallic zinc in ethyl alcohol. It is also made commercially from propane in natural gas by progressive thermal chlorination.
    [Show full text]
  • Environmental Properties of Chemicals Volume 2
    1 t ENVIRONMENTAL 1 PROTECTION Esa Nikunen . Riitta Leinonen Birgit Kemiläinen • Arto Kultamaa Environmental properties of chemicals Volume 2 1 O O O O O O O O OO O OOOOOO Ol OIOOO FINNISH ENVIRONMENT INSTITUTE • EDITA Esa Nikunen e Riitta Leinonen Birgit Kemiläinen • Arto Kultamaa Environmental properties of chemicals Volume 2 HELSINKI 1000 OlO 00000001 00000000000000000 Th/s is a second revfsed version of Environmental Properties of Chemica/s, published by VAPK-Pub/ishing and Ministry of Environment, Environmental Protection Department as Research Report 91, 1990. The pubiication is also available as a CD ROM version: EnviChem 2.0, a PC database runniny under Windows operating systems. ISBN 951-7-2967-2 (publisher) ISBN 952-7 1-0670-0 (co-publisher) ISSN 1238-8602 Layout: Pikseri Julkaisupalvelut Cover illustration: Jussi Hirvi Edita Ltd. Helsinki 2000 Environmental properties of chemicals Volume 2 _____ _____________________________________________________ Contents . VOLUME ONE 1 Contents of the report 2 Environmental properties of chemicals 3 Abbreviations and explanations 7 3.1 Ways of exposure 7 3.2 Exposed species 7 3.3 Fffects________________________________ 7 3.4 Length of exposure 7 3.5 Odour thresholds 8 3.6 Toxicity endpoints 9 3.7 Other abbreviations 9 4 Listofexposedspecies 10 4.1 Mammais 10 4.2 Plants 13 4.3 Birds 14 4.4 Insects 17 4.5 Fishes 1$ 4.6 Mollusca 22 4.7 Crustaceans 23 4.8 Algae 24 4.9 Others 25 5 References 27 Index 1 List of chemicals in alphabetical order - 169 Index II List of chemicals in CAS-number order
    [Show full text]
  • Cyclobutane Derivatives in Drug Discovery
    Cyclobutane Derivatives in Drug Discovery Overview Key Points Unlike larger and conformationally flexible cycloalkanes, Cyclobutane adopts a rigid cyclobutane and cyclopropane have rigid conformations. Due to the ring strain, cyclobutane adopts a rigid puckered puckered conformation Offer ing advantages on (~30°) conformation. This unique architecture bestowed potency, selectivity and certain cyclobutane-containing drugs with unique pharmacokinetic (PK) properties. When applied appropriately, cyclobutyl profile. scaffolds may offer advantages on potency, selectivity and pharmacokinetic (PK) profile. Bridging Molecules for Innovative Medicines 1 PharmaBlock designs and Cyclobutane-containing Drugs synthesizes over 1846 At least four cyclobutane-containing drugs are currently on the market. cyclobutanes, and 497 Chemotherapy carboplatin (Paraplatin, 1) for treating ovarian cancer was cyclobutane products are prepared to lower the strong nephrotoxicity associated with cisplatin. By in stock. CLICK HERE to replacing cisplatin’s two chlorine atoms with cyclobutane-1,1-dicarboxylic find detailed product acid, carboplatin (1) has a much lower nephrotoxicity than cisplatin. On information on webpage. the other hand, Schering-Plough/Merck’s hepatitis C virus (HCV) NS3/4A protease inhibitor boceprevir (Victrelis, 2) also contains a cyclobutane group in its P1 region. It is 3- and 19-fold more potent than the 1 corresponding cyclopropyl and cyclopentyl analogues, respectively. Androgen receptor (AR) antagonist apalutamide (Erleada, 4) for treating castration-resistant prostate cancer (CRPC) has a spirocyclic cyclobutane scaffold. It is in the same series as enzalutamide (Xtandi, 3) discovered by Jung’s group at UCLA in the 2000s. The cyclobutyl- (4) and cyclopentyl- derivative have activities comparable to the dimethyl analogue although the corresponding six-, seven-, and eight-membered rings are slightly less 2 active.
    [Show full text]
  • Euthanasia of Experimental Animals
    EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4.
    [Show full text]
  • Toxicological and Pharmacological Profile of Amanita Muscaria (L.) Lam
    Pharmacia 67(4): 317–323 DOI 10.3897/pharmacia.67.e56112 Review Article Toxicological and pharmacological profile of Amanita muscaria (L.) Lam. – a new rising opportunity for biomedicine Maria Voynova1, Aleksandar Shkondrov2, Magdalena Kondeva-Burdina1, Ilina Krasteva2 1 Laboratory of Drug metabolism and drug toxicity, Department “Pharmacology, Pharmacotherapy and Toxicology”, Faculty of Pharmacy, Medical University of Sofia, Bulgaria 2 Department of Pharmacognosy, Faculty of Pharmacy, Medical University of Sofia, Bulgaria Corresponding author: Magdalena Kondeva-Burdina ([email protected]) Received 2 July 2020 ♦ Accepted 19 August 2020 ♦ Published 26 November 2020 Citation: Voynova M, Shkondrov A, Kondeva-Burdina M, Krasteva I (2020) Toxicological and pharmacological profile of Amanita muscaria (L.) Lam. – a new rising opportunity for biomedicine. Pharmacia 67(4): 317–323. https://doi.org/10.3897/pharmacia.67. e56112 Abstract Amanita muscaria, commonly known as fly agaric, is a basidiomycete. Its main psychoactive constituents are ibotenic acid and mus- cimol, both involved in ‘pantherina-muscaria’ poisoning syndrome. The rising pharmacological and toxicological interest based on lots of contradictive opinions concerning the use of Amanita muscaria extracts’ neuroprotective role against some neurodegenerative diseases such as Parkinson’s and Alzheimer’s, its potent role in the treatment of cerebral ischaemia and other socially significant health conditions gave the basis for this review. Facts about Amanita muscaria’s morphology, chemical content, toxicological and pharmacological characteristics and usage from ancient times to present-day’s opportunities in modern medicine are presented. Keywords Amanita muscaria, muscimol, ibotenic acid Introduction rica, the genus had an ancestral origin in the Siberian-Be- ringian region in the Tertiary period (Geml et al.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Strychnine Poisoning
    0++- Poison HOTLINE Partnership between UnityPoint Health and University of Iowa Hospitals and Clinics November 2013 Strychnine Poisoning Strychnine is a chemical naturally found in the seeds of the tree Strychnos nux- vomica. It is mainly used as a pesticide to control rats, moles, gophers, and coyotes. Commercial baits are pelleted and often dyed red or green. Strychnine has on rare occasions been found to be mixed with street drugs such as LSD, heroin, and cocaine. Strychnine is a white, odorless, bitter tasting crystalline powder that can be taken by mouth, inhaled or given intravenously. Strychnine is highly toxic and Did you know …… only a small amount is needed to produce severe health effects in people. As little as 30 mg may cause death in an adult. Vaporizing alcohol and “smoking” the vapors (inhaling Strychnine blocks the action of the neurotransmitter glycine which controls how is a more accurate term) is a nerve signals are sent to muscles. Glycine is an inhibitory neurotransmitter and new method for alcohol works like an “off switch” for muscles. When this “off switch” is not working consumption. The alcohol is because it is being blocked by strychnine, muscles throughout the body have poured into a vaporizing severe, painful spasms. While these spasms may look like the patient is having machine or over dry ice and a seizure, it is not a true seizure and there is no post-ictal phase. Repetitive inhaled. The alcohol enters muscle spasms caused by strychnine will lead to fever, muscle break down the lungs where it is rapidly (rhabdomyolysis), severe metabolic acidosis and respiratory failure.
    [Show full text]
  • A Systematic Review on Main Chemical Constituents of Papaver Bracteatum
    Journal of Medicinal Plants A Systematic Review on Main Chemical Constituents of Papaver bracteatum Soleymankhani M (Ph.D. student), Khalighi-Sigaroodi F (Ph.D.)*, Hajiaghaee R (Ph.D.), Naghdi Badi H (Ph.D.), Mehrafarin A (Ph.D.), Ghorbani Nohooji M (Ph.D.) Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran * Corresponding author: Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, P.O.Box: 33651/66571, Karaj, Iran Tel: +98 - 26 - 34764010-9, Fax: +98 - 26-34764021 E-mail: [email protected] Received: 17 April 2013 Accepted: 12 Oct. 2014 Abstract Papaver bracteatum Lindly (Papaveraceae) is an endemic species of Iran which has economic importance in drug industries. The main alkaloid of the plant is thebaine which is used as a precursor of the semi-synthetic and synthetic compounds including codeine and naloxone, respectively. This systematic review focuses on main component of Papaver bracteatum and methods used to determine thebaine. All studies which assessed the potential effect of the whole plant or its extract on clinical or preclinical studies were reviewed. In addition, methods for determination of the main components, especially thebaine, which have been published from 1948 to March 2013, were included. Exclusion criteria were agricultural studies that did not assess. This study has listed alkaloids identified in P. bracteatum which reported since 1948 to 2013. Also, the biological activities of main compounds of Papaver bracteatum including thebaine, isothebaine, (-)-nuciferine have been reviewed. As thebaine has many medicinal and industrial values, determination methods of thebaine in P. bracteatum were summarized. The methods have being used for determination of thebaine include chromatographic (HPLC, GC and TLC) and non chromatographic methods.
    [Show full text]
  • DOCUMENT RESUME ED 300 697 CG 021 192 AUTHOR Gougelet, Robert M.; Nelson, E. Don TITLE Alcohol and Other Chemicals. Adolescent A
    DOCUMENT RESUME ED 300 697 CG 021 192 AUTHOR Gougelet, Robert M.; Nelson, E. Don TITLE Alcohol and Other Chemicals. Adolescent Alcoholism: Recognizing, Intervening, and Treating Series No. 6. INSTITUTION Ohio State Univ., Columbus. Dept. of Family Medicine. SPONS AGENCY Health Resources and Services Administration (DHHS/PHS), Rockville, MD. Bureau of Health Professions. PUB DATE 87 CONTRACT 240-83-0094 NOTE 30p.; For other guides in this series, see CG 021 187-193. AVAILABLE FROMDepartment of Family Medicine, The Ohio State University, Columbus, OH 43210 ($5.00 each, set of seven, $25.00; audiocassette of series, $15.00; set of four videotapes keyed to guides, $165.00 half-inch tape, $225.00 three-quarter inch tape; all orders prepaid). PUB TYPE Guides - Classroom Use - Materials (For Learner) (051) -- Reports - General (140) EDRS PRICE MF01 Plus Plstage. PC Not Available from EDRS. DESCRIPTORS *Adolescents; *Alcoholism; *Clinical Diagnosis; *Drug Use; *Family Problems; Physician Patient Relationship; *Physicians; Substance Abuse; Units of Study ABSTRACT This document is one of seven publications contained in a series of materials for physicians on recognizing, intervening with, and treating adolescent alcoholism. The materials in this unit of study are designed to help the physician know the different classes of drugs, recognize common presenting symptoms of drug overdose, and place use and abuse in context. To do this, drug characteristics and pathophysiological and psychological effects of drugs are examined as they relate to administration,
    [Show full text]
  • Divergent Synthesis of Cyclopropane-Containing Fragments and Lead-Like Compounds for Drug Discovery
    Divergent Synthesis of Cyclopropane-Containing Fragments and Lead-Like Compounds for Drug Discovery A Thesis submitted by Stephen John Chawner In partial fulfilment of the requirement for the degree of DOCTOR OF PHILOSOPHY Department of Chemistry Imperial College London South Kensington London SW7 2AZ United Kingdom 2017 1 I confirm that the work presented within this document is my own. Clear acknowledgement has been made when referring to the work of others, or where help has been received. The copyright of this thesis rests with the author and is made available under a Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or transmit the thesis on the condition that they attribute it, that they do not use it for commercial purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, researchers must make clear to others the licence terms of this work. 2 Acknowledgements Firstly, I would like to thank Imperial College London and Eli Lilly whose combined generosity through a CASE award made my PhD financially possible. I would like to thank my academic supervisor Dr James Bull for providing me with the opportunity to undertake a PhD in his group. I am grateful for the chemistry knowledge that he has shared, his encouragement to present at conferences and the freedom to follow new project ideas. In addition to funding, the CASE award provided me with the opportunity to collaborate with Dr Manuel Cases-Thomas at Erl Wood. Manuel was a constant source of enthusiasm throughout my PhD and has been a joy to work with.
    [Show full text]
  • Increased NMDA Receptor Inhibition at an Increased Sevoflurane MAC Robert J Brosnan* and Roberto Thiesen
    Brosnan and Thiesen BMC Anesthesiology 2012, 12:9 http://www.biomedcentral.com/1471-2253/12/9 RESEARCH ARTICLE Open Access Increased NMDA receptor inhibition at an increased Sevoflurane MAC Robert J Brosnan* and Roberto Thiesen Abstract Background: Sevoflurane potently enhances glycine receptor currents and more modestly decreases NMDA receptor currents, each of which may contribute to immobility. This modest NMDA receptor antagonism by sevoflurane at a minimum alveolar concentration (MAC) could be reciprocally related to large potentiation of other inhibitory ion channels. If so, then reduced glycine receptor potency should increase NMDA receptor antagonism by sevoflurane at MAC. Methods: Indwelling lumbar subarachnoid catheters were surgically placed in 14 anesthetized rats. Rats were anesthetized with sevoflurane the next day, and a pre-infusion sevoflurane MAC was measured in duplicate using a tail clamp method. Artificial CSF (aCSF) containing either 0 or 4 mg/mL strychnine was then infused intrathecally at 4 μL/min, and the post-infusion baseline sevoflurane MAC was measured. Finally, aCSF containing strychnine (either 0 or 4 mg/mL) plus 0.4 mg/mL dizocilpine (MK-801) was administered intrathecally at 4 μL/min, and the post- dizocilpine sevoflurane MAC was measured. Results: Pre-infusion sevoflurane MAC was 2.26%. Intrathecal aCSF alone did not affect MAC, but intrathecal strychnine significantly increased sevoflurane requirement. Addition of dizocilpine significantly decreased MAC in all rats, but this decrease was two times larger in rats without intrathecal strychnine compared to rats with intrathecal strychnine, a statistically significant (P < 0.005) difference that is consistent with increased NMDA receptor antagonism by sevoflurane in rats receiving strychnine.
    [Show full text]